No abstract

Utilization of low-cost, abundant and biomaterials is highly recommended for sustainable environment protection. This study presents a comparative analysis on the preparation, characterization and cost analysis of the novel activated biochar (BTS) and activated hydrochar (HTS). Teff (Eragrostis tef) straw was used as a precursor for producing BTS and HTS through pyrolysis and hydrothermal carbonization process, respectively. Both chars were further activated using 30 wt% H 3 PO 4 for 3 h activation time. The physicochemical properties of both chars were compared by different characterization techniques including BET, FTIR, XRD, SEM, and TGA. Briefly, BTS exhibited heterogeneous surface structures and comparatively larger specific surface area (627.7 m 2 /g) than that of HTS (43.8 m 2 /g) with the smooth coalesced carbon layer and dull surface edges. The XRD analysis revealed the amorphous character of HTS which is dominantly composed of AlPO 4 , whilst indicating BTS to be the crystalline structure with the very trivial amount of impurities. The oxygen-containing functional groups increased for HTS in comparison to BTS. Thermogravimetric analysis showed that HTS exhibited better thermal behaviors. Estimated costs incurred in the production of the HTS were found to be cheaper than compared to BTS. Overall, the experiment result suggested that Teff straw could have the potential for producing a low cost activated chars.

SETTING: Active pharmacovigilance (PV) is recommended for TB programmes, notably for multidrug-resistant TB (MDR-TB) patients treated with new drugs. Launched with the support of UNITAID in April 2015, endTB (Expand New Drug markets for TB) facilitated treatment with bedaquiline (BDQ) and/or delamanid of >2600 patients in 17 countries, and contributed to the creation of a central PV unit (PVU).OBJECTIVE: To explain the endTB PVU process by describing the serious adverse events (SAEs) experienced by patients who received BDQ-containing regimens.DESIGN: The overall PV strategy was in line with the ‘advanced´ WHO active TB drug safety monitoring and management (aDSM) system. All adverse events (AEs) of clinical significance were followed up; the PVU focused on signal detection from SAEs.RESULTS and CONCLUSION: Between 1 April 2015 and 31 March 2019, the PVU received and assessed 626 SAEs experienced by 417 BDQ patients. A board of MDR-TB/PV experts reviewed unexpected and possibly drug-related SAEs to detect safety signals. The experts communicated on clusters of risks factors, notably polypharmacy and off-label drug use, encouraging a patient-centred approach of care. Organising advanced PV in routine care is possible but demanding. It is reasonable to expect local/national programmes to focus on clinical management, and to limit reporting to aDSM systems to key data, such as the SAEs.

No abstract

The transfer of these wastes, as well as their controlling framework, has got attention. The waste management and utilization approaches are a fundamental issue all over the